공시 • May 23
Genvor Incorporated Appoints Donald Kalkofen as Chief Financial Officer Genvor Incorporated announced the appointment of Donald Kalkofen as Chief Financial Officer. In this role, Mr. Kalkofen will lead Genvor’s financial strategy as the company advances its dual-market commercialization plans across agriculture and human health and wellness. Mr. Kalkofen brings more than 20 years of Chief Financial Officer experience leading finance and operations across biotechnology, financial services, and technology, with a proven track record of guiding companies through initial public offerings and complex capital markets transactions. Most recently, he served as Chief Financial Officer of Alpha Cognition Inc., a publicly traded CNS-focused biotechnology company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s, where he led the preparations for the company’s successful NASDAQ listing and helped to establish new banking, audit committee, and investor relations functions. Prior to Alpha Cognition, Mr. Kalkofen served as Chief Financial Officer of Protagonist Therapeutics, a publicly traded clinical-stage biopharmaceutical company, where he helped guide the company’s strong growth and supported the company’s successful SOX 404(b) implementation. Earlier in his career, Mr. Kalkofen held Chief Financial Officer and senior finance leadership roles at Symantec Corporation and West Coast Bancorp, where he took the bank public on NASDAQ and led growth from $90 million to $1.5 billion in assets. Mr. Kalkofen is a Certified Public Accountant (inactive) and holds a Bachelor of Arts in Accounting from Washington State University. 공시 • Feb 11
Genvor, Inc. Announces the Publication of Peer-Reviewed Research Validated Its Proprietary Agm182 Antifungal Peptide Technology in Phytofrontiers Genvor Inc. announced the publication of peer-reviewed research validating its proprietary AGM182 antifungal peptide technology in PhytoFrontiers™?, a journal of the American Phytopathological Society. The study, conducted in collaboration with the United States Department of Agriculture's Agricultural Research Service (USDA-ARS), demonstrates that transgenic corn expressing AGM182 achieves significant pre-harvest resistance to Aspergillus flavus and aflatoxin contamination. Aflatoxins are naturally occurring toxic and carcinogenic compounds produced by Aspergillus flavus that contain corn and other crops, posing significant risks to human and animal health. Economic losses fromungal diseases in corn are substantial, with total annual U.S. losses estimated between $3 billion and $5 billion. Aflatoxin contamination alone has potential annual market impacts ranging from approximately $52 million in lower-risk years to $1.68 billion in high-risk years. The peer-reviewed publication follows Genvor's November 2025 announcement that the USPTO issued U.S. Patent No. 12,458,684 for transgenic corn with antifungal peptide AGM182, co-assigned with the USDA. Together, the patent and publication provide both intellectual property protection and independent scientific validation of the technology's commercial potential. The research was conducted at the USDA-ARS Food and Feed Safety Research Unit at the Southern Regional Research Center in New Orleans, Louisiana, in collaboration with scientists from Tuskegee University and Genvor. The study builds on Genvor's over 7-year Cooperative Research and Development Agreement (CRADA) with the USDA-ARS, which focuses on developing corn varieties resistant to pre-harvest aflatoxin contamination. 공시 • Jan 28
Genvor, Inc. Appoints Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, Effective February 2, 2026 Genvor Inc. announced the appointment of Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, effective February 2, 2026. In this role, Dr. Stavrides will lead Genvor’s commercial strategy and execution, focusing on expanding strategic partnerships, licensing agreements, and collaboration opportunities with global agricultural companies. Dr. Stavrides brings more than 15 years of corporate experience in agrochemicals and biologicals, most recently serving as Global Product Management Lead, Biocontrols, at Syngenta. During his tenure, Dr. Stavrides and his team led the commercial evaluation of over 500 biological product concepts, managed over a dozen external collaborations, and oversaw over 50 product launches globally (microbials, extracts, pheromones), quadrupling revenues over a seven-year period. Previously, Dr. Stavrides held various global regulatory, strategy and marketing positions, in both agrochemicals and biocontrols. He has also served as company representative to the International Biocontrol Manufacturers Association (IBMA) for several years. Dr. Stavrides is a biochemist and also holds a Ph.D. in Genomics from Cambridge University (Human Genome Project) and an MBA from INSEAD. 공시 • Dec 12
Genvor Incorporated Auditor Raises 'Going Concern' Doubt Genvor Incorporated filed its 10-K on Dec 10, 2025 for the period ending Sep 30, 2025. In this report its auditor, Novogradac & Company LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern. 공시 • Dec 06
Genvor Incorporated announced that it expects to receive $7 million in funding Genvor Incorporated announced that it will receive $70,00,000 in funding on December 5, 2025. The company will issue common shares and warrants in the transaction. The minimum investment accepted from any outside investor is $10,000. The company will issue securities pursuant to exemption provided under Regulation D. 공시 • Aug 14
Genvor Incorporated announced delayed 10-Q filing On 08/13/2025, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • May 13
Genvor Incorporated announced delayed 10-Q filing On 05/12/2025, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Feb 19
Genvor Incorporated announced delayed 10-Q filing On 02/18/2025, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Feb 01
Genvor Incorporated announced delayed annual 10-K filing On 01/31/2025, Genvor Incorporated announced that they will be unable to file their next 10-K by the deadline required by the SEC. 공시 • Oct 23
Genvor Incorporated Announces the Resignation of Judith S. Miller as Member of the Board of Directors On August 7, 2024, Judith S. Miller resigned as a member of the Board of Directors of Genvor Incorporated (the Company). 공시 • Aug 16
Genvor Incorporated announced delayed 10-Q filing On 08/15/2024, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Jan 18
Genvor Incorporated Appoints Judith Miller as Chief Business Officer Genvor Incorporated announced Judith Miller has been asked to remain and transition from her successful Interim Chief Executive Officer position to serve as Chief Business Officer. 공시 • Jan 17
Genvor Incorporated Announces CEO Changes Genvor Incorporated announced Chad Pawlak, Sr., global Agribusiness executive, has been appointed as Chief Executive Officer of Genvor, effective immediately. Judith Miller has been asked to remain and transition from her successful Interim Chief Executive Officer position to serve as Chief Business Officer. Chad Pawlak, Sr. brings over 30 years of experience with a proven track record of driving revenue growth and fostering strategic partnerships across agribusiness, regenerative agriculture, carbon marketing, food, and sustainability - particularly in soil and water conservation. He has a deep understanding of regenerative agriculture, biotechnology, crop cultivation, livestock management, dairy production, and consumer packaged goods (CPG). Most recently he was Chief Executive Officer of Locus Agricultural Solutions, an agricultural biological company, where he led the strategic growth plan through cross-functional collaboration, resulting in over 350,000 acres of enrollment in a nature-based carbon credit project utilizing a biological product as the practice change. Chad has previous experience as the U.S.-Canada Crop & Plant Protection Business Director Lead - Botanicals for MGK (a part of Valent USA & Sumitomo Chemical). In this role, he was responsible for the overall design of the strategic business plan of the $30 million Botanical & Organic Crop Protection segments in the U.S. & Canada. He holds an MBA from the Jack Welch Management Institute and BS & AOS in Marketing and Advertising/Public Relations from Johnson & Wales University.